ONCY - Oncolytics Biotech Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.1200
+0.0200 (+1.82%)
At close: 3:59PM EST

1.1500 +0.03 (2.68%)
Pre-Market: 8:36AM EST

Stock chart is not supported by your current browser
Previous Close1.1000
Open1.1000
Bid1.1000 x 1800
Ask1.2900 x 900
Day's Range1.0500 - 1.1200
52 Week Range0.3500 - 2.5000
Volume446,818
Avg. Volume582,223
Market Cap29M
Beta (3Y Monthly)2.57
PE Ratio (TTM)N/A
EPS (TTM)-0.8250
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Oncolytics Biotech(R) Announces Abstract Outlining Potential New Biomarker to be Presented at the 2020 Gastrointestinal Cancers Symposium

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / December 12, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today ...

  • ACCESSWIRE

    Oncolytics Biotech(R) Announces Positive Multiple Myeloma Data Presented at the 61st Annual Meeting & Exposition of the American Society of Hematology

    Pre-clinical and clinical data demonstrate synergies between pelareorep and the proteasome inhibitor carfilzomib through inflammation, apoptosis and tumor responses Data provides scientific rationale supporting ...

  • ACCESSWIRE

    Oncolytics Biotech(R) Regains Compliance with Nasdaq Minimum Bid Price Requirement

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / December 6, 2019 / Oncolytics Biotech® Inc. (ONCY)(ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it received written notice from Nasdaq stating that it's minimum bid price deficiency has been cured, it is in compliance with the applicable listing standard and the matter is now closed. Oncolytics had previously been notified by Nasdaq on September 17, 2019 that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. In order to regain compliance with Listing Rule 5550(a)(2), the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days.

  • ACCESSWIRE

    Oncolytics Biotech(R) Presents Clinical Data at the Fifth Annual Oncolytic Virotherapy Conference Highlighting Definitive Evidence of Systemic Delivery and Replication of Pelareorep in Tumor Tissue

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / December 3, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Matt Coffey, President & CEO of Oncolytics Biotech, will be presenting on a panel as well as delivering a corporate presentation on systemic delivery tomorrow at the Oncolytic Virotherapy Conference. Dr. Coffey's corporate presentation will focus on a recently announced metanalysis of 13 clinical studies and how this intravenous-related data is driving the clinical programs of Oncolytics.

  • Companies Like Oncolytics Biotech (TSE:ONC) Can Be Considered Quite Risky
    Simply Wall St.

    Companies Like Oncolytics Biotech (TSE:ONC) Can Be Considered Quite Risky

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • ACCESSWIRE

    Oncolytics Biotech(R) Reports 2019 Third Quarter Financial Results and Operational Highlights

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 12, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced its financial results and operational highlights for the quarter ended September 30, 2019. "We finished the third quarter with a little over twelve million dollars on the balance sheet and have since added to that balance with warrants exercised since the quarter's end" said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. "The quarter was marked by continued clinical execution and additional clinical validation of our systemically delivered oncolytic virus, as we continued to advance two key clinical studies that will determine the design of the phase three program for pelareorep in metastatic breast cancer.

  • ACCESSWIRE

    Oncolytics Biotech(R) Announces Exercise of Warrants

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 12, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the exercise of warrants from it's August 2019 financing. The Company announced the exercise of approximately 1.4 million warrants, at an exercise price of USD $0.90, for net proceeds of approximately USD $1,250,000. "We are very happy to see these warrants exercised so early," said Dr. Matt Coffey, President and CEO of Oncolytics Biotech.

  • ACCESSWIRE

    Oncolytics Biotech(R) Announces AWARE-1 Data Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 8, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, announced a poster presentation today at the annual meeting of the Society for Immunotherapy of Cancer (SITC), highlighting data from the AWARE-1 study in early breast cancer. "This is the first-time our biomarker data from AWARE-1 has been presented at a major academic conference," said Dr. Rita Laeufle, Chief Medical Officer of Oncolytics Biotech. "The primary objective of this study is to evaluate changes in the immune environment of patients diagnosed with early stage breast cancer using our biomarker of T cell clonality measured by CelTIL score.

  • ACCESSWIRE

    Oncolytics Biotech(R) Announces Abstract Published for the 61st Annual Meeting & Exposition of the American Society of Hematology

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 7, 2019 / Oncolytics Biotech® Inc. (ONCY)(ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an abstract highlighting the pre-clinical results of combining pelareorep with the proteasome inhibitor carfilzomib in the treatment of multiple myeloma. The abstract was published online as part of the 2019 American Society of Hematology Annual Meeting & Exhibition. The abstract, titled, "Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma" describes the synergies between proteasome inhibitors and pelareorep concerning immuno-cellular changes and response in multiple myeloma patients.

  • ACCESSWIRE

    Oncolytics Biotech(R) Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 6, 2019 / Oncolytics Biotech® Inc. (ONCY)(ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that positive results from its previously announced phase 1b REO 024 study of pelareorep in combination with pembrolizumab (Merck's Keytruda®) have been published in the peer-reviewed medical journal Clinical Cancer Research, a journal of the American Association for Cancer Research. The study of 11 patients was conducted by Principal Investigator, Dr. Devalingam Mahalingam, Associate Professor of Medicine at Northwestern University Feinberg School of Medicine and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. "Pelareorep and pembrolizumab added to chemotherapy was safe and well-tolerated and demonstrated encouraging efficacy results," said Dr. Mahalingam.

  • ACCESSWIRE

    Oncolytics Biotech(R) to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / November 5, 2019 / Oncolytics Biotech® Inc. (ONCY)(ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will host a conference call for Analysts and Institutional Investors at 5:00 p.m. ET on Tuesday, November 12, 2019 following release of its third quarter 2019 financial results. Overseas callers should contact investor relations for the toll-free dial information for their country. A live webcast of the call will be accessible on the Investor Relations page of Oncolytics' website at www.oncolyticsbiotech.com and will be archived for three months.

  • ACCESSWIRE

    Oncolytics Biotech(R) Provides Update on Partner Adlai Nortye’s Clinical Progress

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 31, 2019 / Oncolytics Biotech® Inc. (ONCY)(ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today provided an update on its partner, Adlai Nortye's, clinical progress and approval by the National Medical Products Administration (NMPA) of China for initiating a phase 3 clinical trial for pelareorep. "We congratulate Adlai on this significant regulatory and business achievement that paves the way for pelareorep's development in the world's second largest pharmaceutical market," said Andrew de Guttadauro, President of Oncolytics Biotech U.S. and Global Head of Business Development.

  • ACCESSWIRE

    Oncolytics Biotech(R) and PrECOG Announce Collaboration for BRACELET-1 (PrE0113) Study in Metastatic Breast Cancer

    SAN DIEGO, CA and CALGARY, AB and PHILADELPHIA, PA / ACCESSWIRE / October 22, 2019 / Oncolytics Biotech® Inc. (ONCY)(ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, and PrECOG LLC, a leading cancer research network, today announced their collaboration in which PrECOG will run the BRACELET-1 (PrE0113) study. The principal investigator will be Kathy Miller, MD, Ballve-Lantero Professor of Oncology at Indiana University School of Medicine and Associate Director of Clinical Research at Indiana University Melvin and Bren Simon Cancer Center, and PrECOG member. The study will take place in 15 centers in the United States and will evaluate the ability of pelareorep to make tumors immunologically visible to checkpoint inhibitors.

  • ACCESSWIRE

    Oncolytics Biotech(R) Appoints Experienced Financial and Strategic Leader Leonard Kruimer to Board of Directors

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 17, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, is pleased to announce the appointment of Leonard Kruimer, MBA, CPA, to Oncolytics' Board of Directors. Mr. Kruimer has more than 30 years of experience in corporate finance, planning and strategy, including 20 years in senior management positions in private and publicly listed biotechnology and life science companies. Notably, Mr. Kruimer served as CFO and Executive Committee Member of the Netherlands-based vaccine company Crucell from 1998 through 2011, and an integral part of the corporate sale to Johnson & Johnson for US$2.3 billion.

  • ACCESSWIRE

    Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 15, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the results of a metanalysis of 13 clinical studies of the Company's systemically delivered oncolytic reovirus, pelareorep, were presented during a podium presentation at the annual International Oncolytic Virus Conference (IOVC), hosted at the Mayo Clinic in Rochester, MN on October 9-12, 2019. The analyses examined the effectiveness of viral replication within the tumors of patients treated systemically with pelareorep. The data demonstrated that, unlike other oncolytic viruses that require intra-tumoral delivery, intravenous (IV) systemic delivery of pelareorep resulted in 81% of patient tumor samples across multiple types of cancer testing positive for virus replication, with no infection in normal tissue.

  • ACCESSWIRE

    Oncolytics Biotech(R) Announces Abstract to be Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 1, 2019 / Oncolytics Biotech ® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today ...

  • ACCESSWIRE

    Oncolytics Biotech CEO, Matt Coffey, Honored with Scientific Achievement and Innovation Award by BioAlberta

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 30, 2019 / Oncolytics Biotech® Inc. (ONCY)(ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that its President and Chief Executive Officer, Matt Coffey, Ph.D., MBA, was presented with the Scientific Achievement and Innovation Award by BioAlberta, the province's life sciences industry association. "I am honored to receive this recognition from BioAlberta for my work in oncolytic viruses, which started a little more than twenty years ago at the University of Calgary," said Dr. Coffey. Most importantly, we've learned about the ability of oncolytic viruses to wake up the immune system.

  • ACCESSWIRE

    Oncolytics Biotech(R) Announces Upcoming Presentation at the 12th Annual International Oncolytics Virus Conference

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 25, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it will have an oral presentation at the 12th Annual International Oncolytic Virus Conference. The conference takes place at the Mayo Civic Center in Rochester, Minnesota, from October 9 - 12. The presentation, "Systemic administration of oncolytic reovirus, pelareorep, a metanalysis on the efficiency of tumor delivery", by Grey Wilkinson, PhD, Scientist of Translational Medicine at Oncolytics Biotech, will examine the efficiency of viral delivery and replication in tumor tissue across several clinical studies.

  • ACCESSWIRE

    Oncolytics Biotech(R) Announces Upcoming Conference Participation

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 23, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY)(TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today ...

  • ACCESSWIRE

    Oncolytics Biotech(R) Receives Nasdaq Notification Letter

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 20, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq"). The letter notifies the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market, since the closing bid price for the Company's common shares listed on Nasdaq was below USD $1.00 for 30 consecutive trading days.

  • ACCESSWIRE

    Oncolytics Biotech(R) to Present at the Ladenburg Thalmann Healthcare Conference

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 17, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Matt Coffey, President & CEO of Oncolytics Biotech, will present at the Ladenburg Thalmann Healthcare Conference at 11:00 am Eastern Time on Tuesday, September 24, 2019. A live audio link to the webcast session will be available on the Company's website at http://www.oncolyticsbiotech.com/investor-centre/presentations. Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.

  • ACCESSWIRE

    Oncolytics Biotech(R) to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 5, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Kirk Look, Chief Financial Officer of Oncolytics Biotech, will present at the H.C. Wainwright 21st Annual Global Investment Conference at 5:30 pm Eastern Time on Monday, September 9, 2019. A live audio link to the webcast session will be available on the Company's website at http://www.oncolyticsbiotech.com/investor-centre/presentations. Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.

  • ACCESSWIRE

    Oncolytics Biotech(R) to Host Corporate Update Call to Discuss Recent Highlights and Expanded Catalysts and Milestones

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 4, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced it will host a conference call and live webcast for Analysts and Institutional Investors at 8:30 a.m. ET on Thursday, September 5, 2019. The call will focus on a clinical and business development update, the current financial position and the recently updated list of catalysts and milestones. Overseas callers should contact investor relations for the toll-free dial information for their country.

  • ACCESSWIRE

    Oncolytics Biotech(R) Announces Closing of Its Public Offering of Common Shares and Warrants

    SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / August 16, 2019 / Oncolytics Biotech® Inc. (ONCY)(ONC.TO) (the “Company”), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the closing of its previously announced underwritten public offering (the “Offering”). Oncolytics sold 4,619,773 common shares and warrants to purchase up to 4,619,773 common shares, at a purchase price of USD $0.81 (approximately CDN $1.07) per share and warrant, for gross proceeds of approximately USD $3.7 million (approximately CDN $4.9 million). Oncolytics expects to use the net proceeds from the Offering for research and development activities and working capital purposes.

  • Benzinga

    The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 14) GENMAB A/S/S ADR (NASDAQ: GMAB ) (announced first-half ...